Amy Lyons, VP of Marketing, Sherlock Biosciences
The pandemic helped expose the limited effectiveness of current diagnostic solutions due to cost, labor, and the extensive need for lab equipment and infrastructure. During this time, new companies emerged in the space with solutions that removed barriers to testing and could prove vital to solving global public health challenges now and in the future. Among them was Sherlock Biosciences, which received the first-ever FDA authorization for the use of CRISPR technology for the company’s novel diagnostic platform for the rapid detection of the virus that causes COVID-19. This milestone demonstrated the value of CRISPR and served as a launch pad for Sherlock’s advancements toward future applications that meet the needs of an evolving diagnostic landscape.
Throughout these pivotal growth years for Sherlock, Amy Lyons has been at the heart of it all. She has nourished the team’s vision by providing leadership and counsel in the areas of corporate messaging and branding, content development, and media strategy. Under her guidance, the company has grown it’s social audience by over 250% and secured more than 300 articles in top tier outlets including Wall Street Journal, Financial Times, Bloomberg, Forbes, The Washington Post, Wired, and Fast Company.
Most recently, Amy led communications for Sherlock’s highly successful $80 million Series B financing raise. As part of this communications push, Amy helped secure interviews for Sherlock CEO and President, Bryan Dechairo, with numerous top-tier press, resulting in significant media coverage. While Sherlock is breaking down barriers to democratize diagnostics, Amy’s unbridled passion, dedication, and leadership ensure the company is at the forefront of this vital global health conversation.
